Skip to main content

Table 1 Clinicopathologic characteristics of patients with localized prostate cancer who underwent moderately hypofractionated, intensity-modulated radiotherapy

From: Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer

Characteristic

Number of patients [cases (%)]

Gleason score

 ≤ 6

274 (46.0)

 7

240 (40.3)

 ≥ 8

82 (13.8)

T stage

 T1–T2b

577 (96.8)

 T2c

5 (0.8)

 ≥ T3

14 (2.3)

Pretreatment PSA level (mg/dL)

 ≤ 10

467 (78.4)

 > 10 and ≤ 20

98 (16.4)

 > 20

31 (5.2)

D’Amico category

 Low risk

226 (37.9)

 Intermediate risk

264 (44.3)

 High risk

106 (17.8)

ADT in risk groups

 Low-risk

48 (21.2)

 Intermediate-risk

208 (78.8)

 High-risk

105 (99.1)

  1. PSA prostate-specific antigen, ADT androgen deprivation therapy